SCHEMBL4905366

SCHEMBL4905366

COc1cccc(-c2cnc3ccccc3[n+]2[O-])c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CRHBP P24387 1/20 0.51
CRHR2 Q13324 1/20 0.51
KEAP1 Q14145 1/20 0.51
NFE2L2 Q16236 1/20 0.51
PDGFRB P09619 1/20 0.45
PDGFRA P16234 1/20 0.45
CLK4 Q9HAZ1 2/20 0.44
DYRK1A Q13627 1/20 0.44
RAB9A P51151 4/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
NFKB1 P19838 2/20 0.43
NFKB2 Q00653 2/20 0.43
RELA Q04206 2/20 0.43
TDP1 Q9NUW8 2/20 0.43
MAPT P10636 2/20 0.43
CYP1A2 P05177 3/20 0.42
CYP3A4 P08684 3/20 0.42
CYP2C9 P11712 3/20 0.42
CYP2D6 P10635 2/20 0.42
USP2 O75604 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4897532 0.74 TDP1 (0.39) CRHBPCRHR2KEAP1NFE2L2RAB9A
SCHEMBL4897609 0.73 CYP2A6 (0.46) PDGFRBPDGFRACLK4RAB9ASMN1; SMN2
SCHEMBL4907642 0.71 ALDH1A1 (0.48) RAB9ASMN1; SMN2NFKB1NFKB2RELA
SCHEMBL3007825 0.70 PDGFRB (0.69) PDGFRBPDGFRACLK4DYRK1ARAB9A
SCHEMBL14164167 0.69 DYRK1A (0.45) CLK4DYRK1ARAB9ASMN1; SMN2NFKB1
SCHEMBL15010394 0.68 CRHBP (1.00) CRHBPCRHR2KEAP1NFE2L2RAB9A
SCHEMBL4905193 0.68 DYRK1A (0.47) CLK4DYRK1ARAB9ASMN1; SMN2TDP1
SCHEMBL14170378 0.68 ERN1 (0.36) CRHBPCRHR2KEAP1NFE2L2RAB9A
SCHEMBL196765 0.66 CYP3A4 (0.73) CLK4DYRK1ACYP1A2CYP3A4CYP2C9
SCHEMBL29489425 0.66 CYP3A4 (0.73) CLK4DYRK1ACYP1A2CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080132698-A1 Use of N-oxide compounds in coupling reactions UNIVERSITY OF OTTAWA 2008-06-05 US disclosed
US-20080132698-A1 Use of N-oxide compounds in coupling reactions UNIVERSITY OF OTTAWA 2008-06-05 US disclosed
US-20080132698-A1 Use of N-oxide compounds in coupling reactions UNIVERSITY OF OTTAWA 2008-06-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080132698-A1 Use of N-oxide compounds in coupling reactions CYP4X1, CYP4F3, CYP1A2 CRHBP 4783/4885CRHR2 3045/4885KEAP1 662/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.